Key Highlights
- argenx shares rallied 16% to end at $987.84.
- The Phase 3 ALKIVIA trial of Vyvgart Hytrulo for autoimmune myositis reached its primary endpoint.
- The pooled IMNM/DM group showed a statistically significant 15.4-point TIS improvement versus placebo over 52 weeks.
- The IMNM subset showed notable efficacy, while the DM-only subgroup showed clinically relevant but not statistically significant data.
argenx SE (NASDAQ: ARGX) shares rallied 16% to end at $987.84 after the company reported that its Phase 3 ALKIVIA trial of Vyvgart Hytrulo for autoimmune myositis reached its primary endpoint, highlighting a statistically significant 15.4-point TIS improvement in the pooled IMNM/DM group versus placebo over 52 weeks.
What Happened
Although the DM-only subgroup yielded clinically relevant data without statistical significance, the IMNM subset exhibited notable efficacy, with the overall safety profile remaining consistent with prior efgartigimod clinical studies.
Market Reaction
Shares rallied sharply as investors responded to the trial's success on its primary endpoint and the consistency of the safety profile with prior efgartigimod research, even as the split results between the IMNM and DM subgroups added some nuance to the overall data set.
Outlook
The split results between the IMNM and DM subgroups are likely to be a key focus for regulators and investors as argenx determines its regulatory strategy for Vyvgart Hytrulo in autoimmune myositis.
FAQs
Q: Why did argenx shares rally 16%?
A: Shares rose after the Phase 3 ALKIVIA trial of Vyvgart Hytrulo achieved its primary endpoint in autoimmune myositis, with a statistically significant 15.4-point TIS improvement in the pooled IMNM/DM group.
Q: Did both patient subgroups show statistically significant results?
A: The IMNM subset exhibited notable efficacy, while the DM-only subgroup showed clinically relevant but not statistically significant results.
Q: How did the trial's safety profile compare to prior data?
A: It remained consistent with prior efgartigimod clinical studies.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.